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abstract
Since the creation of the EORTC Headquarters in 1974, major advances have been
made in the methodology used in the design and analysis of cancer clinical trials.
However, the speed of these developments in the ﬁelds of biology, medicine, and
statistics has greatly increased since the turn of the 21st century. These changes
have all become possible because of the increased computer power now available.
The landscape of therapeutic anti-cancer development changed completely with
the advent of the so-called “targeted agents” that treat the underlying molecular
basis of the disease rather than the symptoms of tumor proliferation. The new
challenges posed by the clinical development of these numerous new agents that
are expected to work in often yet-to-be-identiﬁed subgroups of patients induced a
new wave of methodological developments. Some of these were readily embraced
by the EORTC Headquarters statistics department, while others met with opposition.
Our assessment is still in progress in many areas. Trials tend to become increasingly
complex so that their planning relies on an increasing number of unknown
parameters that need to be monitored during the trial itself, one development being
“adaptive” design methodology.
Because the knowledge required to design these new and more complex clinical
trials and associated research program spans more disciplines (biology, genomics,
radiology) and involves specialized knowledge within those disciplines, continued
success requires further developing our partnerships with specialized departments
(imaging, bio-informatics, biology, etc.) within EORTC Headquarters and in EORTC
afﬁliated centers as well as collaborations with specialized statisticians from
academia.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
Since the creation of the EORTC Data Center in 1974,
major advances have been made in the methodology
used in the design and analysis of cancer clinical trials.
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However, the speed of these developments in the ﬁelds
of biology, medicine and statistics has greatly increased
since the turn of the 21st century. These changes have
all become possible because of the increasing computer
power that is now available to these ﬁelds.
Until the late 1990’s, anti-cancer drugs undergoing
clinical development were mostly non-targeted cytotoxic
agents. Their clinical development was carried out in
three major steps: phase I studies to ﬁnd the maximum
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tolerated dose of a drug whose activity (and toxicity)
was assumed to increase with increasing dose; then
phase II trials to identify the cancer types in which the
drug shows some degree of biological anti-cancer activity
(typically assessed in terms of tumor response rate), and
for the most promising drugs, one or several phase III
comparative studies to assess the relative beneﬁt of the
drug in comparison to established standard therapy in
terms of a clinically relevant endpoint (most often overall
survival).
At that time, the methodology for both the design and
the statistical analysis of trials was well established, and
statisticians could do their job with a limited number
of tools. The most commonly used designs for phase II
were developed by Gehan, 1 Fleming 2 and Simon 3 in,
respectively, 1961, 1982 and 1989. In 1974, George and
Desu 4 published formulae for the calculation of sample
size for phase III trials that could be done with a pocket
calculator and tables were published by Freedman 5 in
1982. The Kaplan–Meier estimation of survival curves
has been known since 1958, 6 and Cox 7 published his
regression model in 1982. Randomizing treatments by
minimization was published in 1976, 8 but was not
adopted until the advent of the personal computer. More
advanced developments, such as equivalence studies
and survival estimation in the presence of competing
risks, were approached respectively by Blackwelder 9 and
Gray, 10 both in 1982, whereas the interim monitoring
plans for phase III trials using alpha-spending functions
were published in 1993. 11
Up to 1995, the statistical analysis of studies at the
EORTC Data Center was done using a home-made
VAX-VMS program, “SMART”, that directly accessed the
central EORTC database. It could take several hours for
the analysis program of a phase III trial with a few
hundred patients to run. The results were then manually
transferred from a line-listing into a document that
would be faxed or mailed to the study coordinators.
Shortly thereafter, microcomputers became available
for most EORTC collaborators, and the speed of
information exchange increased a lot thanks to email.
Computer power also increased, and this enabled
statisticians worldwide to put into practice a number
of methodological developments whose implementation
had awaited the computing power that had been
heretofore unavailable.
In parallel, biology met informatics, giving rise to bioin-
formatics and the sophisticated statistical algorithms
upon which DNA sequencing, microarray expression
proﬁling and genomic sequence analysis rely. 12 The
genomic revolution started the dream of personalized
medicine whereby genetic information would help
doctors select the most appropriate drugs to treat a
given patient’s disease. The landscape of therapeutic
anti-cancer development changed completely with the
advent of the so-called “targeted agents” that treat the
underlying molecular basis of the disease rather than the
symptoms of tumor proliferation. The new challenges
posed by the clinical development of these numerous
new agents that are expected to work in often yet-to-
be-identiﬁed subgroups of patients induced a new wave
of methodological developments. Some of these were
readily embraced by the EORTC Headquarters Statistics
Department, while others met with opposition. Our
assessment is still in progress in many areas. Trials tend
to become increasingly complex so that their planning
relies on an increasing number of unknown parameters
that need to be monitored during the trial itself,
one development being “adaptive” design methodology.
Below we will discuss some of these challenges.
2. Early development of targeted agents
2.1. Phase I
Molecularly targeted agents are not expected to have the
same toxicity proﬁle as the classical cytotoxic agents,
and their degree of activity does not necessarily increase
with increasing dose. There is now evidence that the
conventional methodology of phase I oncology clinical
trials may not be appropriate for newer agents such as
molecularly targeted agents (MTAs). 13
The EORTC has launched a new project developing
“Guidelines for the deﬁnition of Dose Limiting Toxicity
(DLT) and Recommended Phase II dose (RP2D) for phase I
clinical trials testing MTAs as single agents”. This project
will be conducted with partners in both academia
and industry and plans to build a data warehouse
at the EORTC Headquarters of closed phase I clinical
trials of single-agent MTAs. Exploration of the data
warehouse will provide information supporting a revised
DLT deﬁnition and approach to the RP2D. The proposal
will be published in a peer-reviewed journal. A parallel
initiative is being conducted in the US and Canada for
phase I trials of combinations of agents.
2.2. Phase II
Although many new compounds enter clinical develop-
ment in oncology, up to 70% of those entering Phase II fail
to make it to Phase III. 14 This can be partially explained
by the fact that although traditional designs developed
in the 1980s for phase II trials (such as the Fleming
design) were efﬁcient at identifying inactive agents, they
have low predictive value for positive phase III results. 15
They were also generally conducted with relatively high
false-positive error rates to keep the false-negative error
rate low, because few compounds were available for
development.
Today, phase II trials need to be designed to have
an improved prediction of successful phase III studies.
For certain cancers in which many new agents are
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in development, it is important to keep the risk of a
false-positive ﬁnding at the end of the phase II to a
minimum. Furthermore, because the newer agents are
expected to slow down or stop tumor proliferation but
are not expected to induce tumor response, progression-
free survival is often the endpoint of today’s phase II
studies. Because patients may remain progressive even
in absence of treatment, because new agents are often
tested upfront in combination with other agents known
to have some activity, and because targeted agents are
sometimes developed in combination with diagnostic
tests and studied in subgroups of patients whose tumor
bears the target of interest, phase II studies at the EORTC
are nowadays most often randomized and include a ref-
erence control treatment group. 16 EORTC Headquarters
has adopted comparative screening phase II designs, 17,18
pick-the-winner designs, 19,20 and marker-based de-
signs. 21 The EORTC also regularly conducts multi-tumor
basket phase II studies through its NOCI network.
In the EORTC Statistics Department, we are constantly
reassessing the methodology that is appropriate for our
phase II trials. Thus, when the Consensus Recommen-
dations from the Clinical Trial Design Task Force of the
National Cancer Institute Investigational Drug Steering
Committee 22 were released, we were pleased to see that
this document perfectly reﬂected our current updated
procedures.
3. Progression-free survival as endpoint
As more effective salvage treatments become available,
many trials in the adjuvant or even metastatic setting
nowadays have progression-free survival (PFS) as primary
endpoint. However, this endpoint is much more difﬁcult
to assess than overall survival: PFS is subject to
measurement errors and imprecision and at risk of
interpretation bias, since the imaging diagnostics involve
a certain degree of human (subjective) interpretation.
Because progression is assessed at scheduled follow-
up visits, a failure that is diagnosed at a given follow-
up visit has in fact occurred in the time interval from
the preceding assessment to the present visit. This
leads to an overestimation of the time to failure. 23,24
The frequency of assessments also directly impacts on
the estimated treatment differences, 23−25 even when
the visits are scheduled symmetrically in the two
randomized treatment groups. Caroll 24 has shown that
the hazard ratio is increasingly biased toward the null
hypothesis of no difference as the interval between
visits lengthens and the frequency of visits declines.
As a consequence, statistical power decreases and the
number of events needed to maintain the speciﬁed
statistical power increases.
From the above remarks, it is clear that artiﬁcial
treatment effect differences may be caused by an
asymmetric schedule of visits between the two groups or
by systematically prolonged delays in observation times
in one arm compared to the other. Simulation studies
have demonstrated that differences in the timing of
disease evaluations can signiﬁcantly bias PFS analyses
to the point of causing an apparent improvement
in outcome when none exists. 23,26 Dancey et al. 27
recommend blinding in trials that use progression-
free survival as endpoint. This is to prevent that
the knowledge of the treatment group inﬂuences the
investigator in the assessments that involve a greater
degree of subjectivity (for example, review of images),
or in the decision to delay treatment and/or visits on
the basis of toxicity or inconvenience for the patient.
Physicians or patients may be biased towards earlier
claims of progression in the control arm that is generally
thought to be the less effective treatment.
In the FDA Guidance, 28 a whole section is devoted
to the statistical methods of analyzing progression-
free survival endpoints. The guidance is often inter-
preted as recommending that patients who stop taking
randomized therapy prior to documented progression
should be censored at the time when the treatment
is stopped. 24 However, this causes obvious problems
in the analysis since such censoring is informative by
construction. Indeed, patients who stop treatment in
absence of progression generally do so either because
of toxicity or because of a general deterioration in their
status that is likely indicative of treatment failure. In
such circumstances, if the prevalence of censoring differs
between arms, naive censoring could lead to extremely
biased results: taken to the extreme, a treatment that
would be so toxic that all patients would stop treatment
due to toxicity would have an estimated progression-free
survival rate of 100% when using the method described
above. Importantly, central review of progression may
induce the same type of problem if it is not conducted
in real-time. If treatment is stopped on the basis of
progression diagnosed by the treating physician and
is later not conﬁrmed by the central review, censoring
the data at the time of change of treatment will also
induce bias in the analysis. The EORTC strongly opposes
this type of analysis being the primary analysis of PFS
in its trials. The EORTC statistics department is also
investigating methods of interval censoring for analyzing
this type of endpoint and pays special attention to
select appropriate assessment schedules when designing
studies that use PFS as endpoint.
4. Predictive markers for response to therapy −
Translational research
Many cancer treatments beneﬁt only a small proportion
of the patients. For such treatments, classical phase III
trials with broad eligibility criteria are inefﬁcient.With an
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Fig. 1 – Predictive markers for beneﬁt from a new experimental treatment. Patients are classiﬁed based on a biomarker
expression level threshold into two groups of differing sensitivity to the experimental treatment (M, Marker expression,
PPV, Positive predictive value).
overall negative result, such studies fail to demonstrate
the beneﬁt of the new treatment when the proportion of
patients who actually beneﬁt from the new treatment is
small, and will result in the over-treatment of patients
who do not beneﬁt from the new treatment. Today, there
is strong biological rationale explaining why some drugs
work in only a selected subpopulation. The identiﬁcation
of the subpopulation of interest is challenging; it requires
the identiﬁcation of predictive classiﬁers to assign
patients to subgroups that beneﬁt (or not) from the
investigated therapy. The predictive classiﬁer may be
based on a single marker or on a group of markers,
such as a molecular signature. The classiﬁer requires in
addition the identiﬁcation of one (or several) thresholds
to classify patients into homogeneous groups that share
a similar likelihood of beneﬁting from the new therapy
(Fig. 1).
Before development of a predictive marker for clinical
use by its formal testing in phase III marker-based
designs described below can begin, a preliminary
exploration is needed to identify the putative predictive
(combination of) markers and the relationship between
marker expression and outcome. This is done at EORTC
through the Translational Research Program.
Such exploration can be done by a retrospective study
of the marker in available tissue of patients with a known
outcome who have been similarly treated in former
studies, or by the prospective planning of marker studies
alongside or as part of ongoing trials.Together, the EORTC
Headquarters Statistics and Translational Research and
Imaging Departments have developed and acquired the
statistical methodology needed for the planning and
high-level analysis of such translational research studies.
In collaboration with the EORTC Imaging Group, the
Statistics Department is also developing methodology for
the exploration and validation of imaging markers.
5. Marker-based phase III trials
Before launching a phase III trial to conﬁrm that
an investigational treatment works preferentially in a
subgroup of patients deﬁned by the expression of a
marker, earlier research must have developed a validated
assay to measure with sufﬁcient accuracy the biomarker
of interest and show that it has good reproducibility
(if this is not attained in the multicenter setting, a
central laboratory should be used). The threshold to
deﬁne the subgroups thought to be more or less sensitive
to the treatment of interest must have been identiﬁed.
This classiﬁer must not only show a strong association
with the outcome of interest (large hazard ratio or
odds ratio) but must also show high speciﬁcity and
positive predictive value for the outcome according to
the treatment. There must be preliminary evidence that
the experimental treatment works best in one of the
marker groups (sensitive subgroup, say Marker +), and
the prevalence of the sensitive subgroup must be known.
Notably, the marker needs not to be a biomarker but
may also be a diagnostic imaging marker or an early
assessment of sensitivity to the treatment (such as with
early PET response). The above elements, while needed,
are often not all fulﬁlled, thereby further complicating
the design of the Phase III.
With reasonable assumptions regarding these ele-
ments, a phase III trial may be envisaged. Such a trial
may take several forms 29 (Figure 2): either the new and
the standard treatment are tested in only the sensitive
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Fig. 2 – Marker-based phase III designs.
subgroup (enrichment design, such as EORTC 40071
testing lapatinib in HER2 positive gastro-esophageal
junction cancer 30), or all patients enter the trial and are
randomized, but a testing strategy is deﬁned upfront
to test if the relative treatment beneﬁt is present in
only one or in both subgroups (marker-by-treatment
“all comers” design, such as the EORTC “p53” trial
10994 that assessed taxane-based versus non-taxane
based chemotherapy for breast cancer 31). More rarely,
the patients are randomized to one of two treatment
strategies: (1) one that is based on knowledge of the
marker or (2) a strategy that does not use the marker
(strategy designs). Trials may also use hybrid designs
whereby only a certain marker-deﬁned subgroup of
patients is randomized but the other patients are kept
in the study and are assigned a speciﬁc treatment,
such as in the EORTC MINDACT trial 32 in which a
patient’s risk of metastases is assessed by two risk scores,
one using genomic information, and the other using
standard clinical and pathological information. Patients
with discordant risk assessments (i.e., the two scores
disagree) are randomized to treatment according to
clinical or genetic risk whereas the patients for whom
the two risk scores agree receive (high risk) or do not
receive (low risk) chemotherapy.
Over the past 15 years, EORTC Headquarters has
acquired expertise in the design and conduct of such
complex trials. We recommend the “all-comers” marker
based design when the new marker is not yet fully
established or validated. Because this design inevitably
leads to conducting a number of tests for treatment
effect in both the whole group and in subgroups,
the analysis plan must be fully pre-speciﬁed using
appropriate measures to control the overall type I error
rate (either through closed-testing procedures or using
split-alpha procedures 33). We also strongly advocate to
pre-specify stopping rules for futility or even inferiority
of the experimental arm in order to stop the study in
the “insensitive subgroup” and convert the trial to an
enrichment design should there be strong evidence that
the experimental treatment does not work or harms
patients not bearing the marker of interest. Whenever
feasible, marker testing prior to entry in the study is also
advocated in order to allow a prospective stratiﬁcation of
the randomization and ensure balanced treatment arms
within subgroups and facilitate design adaptations. An
enrichment design is recommended when the marker
is already well established or when it is unethical to
randomize the Marker-negative patients. For this design,
pretesting of the marker and a rapid assay turnover
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is mandatory. This design is more efﬁcient when the
proportion of sensitive patients is relatively low, so that
testing the new drug in the subgroup thought to be
insensitive is prohibitive. Experience has shown that
due to the dilution of the treatment effect, randomized
strategy designs in general require huge sample sizes and
are thus rarely feasible.
Because of the numerous assumptions made in their
design, marker-based trials require careful monitoring
of: (1) the assay success rate (and homogeneity between
laboratories when several are used), (2) the prevalence
of the marker subgroups, (3) the values of the endpoint
for the reference arm in all subgroups. All of these
factors inﬂuence the power of the tests in the various
populations and the timing of the analyses. Revision
of the sample size calculations must be considered
when necessary. Further trial adaptation may also result
from planned stopping rules or from new information
emerging from other trials. The pan-European PETACC-8
trial, for example, started with an “all comers” design
testing the addition of cetuximab to FOLFOX in com-
pletely resected stage III colon cancer, but ended, after
several amendments, with an enrichment design in the
subgroup of patients presenting with wild-type k-Ras!
A well-informed and experienced IDMC is essential for
performing such a trial.
6. Prognostic factors and nomograms
Using the EORTC clinical trial databases, sometimes
combined with data from other research organizations,
the EORTC Statistics Department has also developed
prognostic models and nomograms for a range of
conditions and endpoints over the years. 34−37 The
development of a prognostic model is not as simple
as using the data at hand to run an automatic model
selection procedure to produce one model that more or
less ﬁts the data. In order to be trustworthy and useful,
prediction models need to:
(1) use variables that are clinically relevant and are
routinely measured in patients;
(2) be robust to small variations in the development
dataset;
(3) show a good discrimination (separates groups with
differing probabilities of the outcome of interest);
(4) show good calibration (predictions match observed
event rates) 38;
(5) the model performance must be validated on an
independent dataset and it must be shown to
outperform all existing models for the intended
clinical use;
(6) model comparisons must be performed using the
same data for all models! 39;
(7) but also, and maybe most importantly, a prediction
model is useful only if it can be shown that the
prediction tools impacts on clinical decisions and that
they lead to improved treatment decisions.
This new challenge is similar to the assessment of
the clinical utility of a new marker to guide treatment
decisions and will require decision-analytic methods to
forecast the impact of the tool. 40
7. Conclusions
Cancer clinical trials are becoming increasingly complex
and challenging for the statistician. Meeting these
challenges increasingly requires EORTC clinical trial
statisticians to acquire more knowledge in other ﬁelds
(biology, genomics, radiology) to be able to develop
new designs and new statistical methods. Because
the knowledge required spans more disciplines and
involves specialized knowledge within those disciplines,
continued success requires further developing our
partnerships with specialized departments (imaging, bio-
informatics, biology, etc.) within EORTC Headquarters
and in EORTC afﬁliated centers as well as collaborations
with specialized statisticians from academia.
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